122 related articles for article (PubMed ID: 36383333)
1. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Mariani A; Zaanan A; Glehen O; Karoui M
Ann Surg Oncol; 2023 Feb; 30(2):816-817. PubMed ID: 36383333
[No Abstract] [Full Text] [Related]
2. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Sundar R; Kim G; Ang JJ; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2023 Mar; 30(3):1889-1890. PubMed ID: 36564654
[No Abstract] [Full Text] [Related]
3. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Sundar R; Kim G; Ang JJ; Lum JHY; Nga ME; Goh GH; Seet JE; Chee CE; Tan HL; Ho J; Ngoi NYL; Lee MXW; Muthu V; Chan GHJ; Pang ASL; Ang YLE; Choo JRE; Lim JSJ; Teh JL; Lwin A; Soon Y; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2022 Dec; 29(13):8597-8605. PubMed ID: 36070113
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan.
Kono K; Yong WP; Okayama H; Shabbir A; Momma T; Ohki S; Takenoshita S; So J
Gastric Cancer; 2017 Mar; 20(Suppl 1):122-127. PubMed ID: 27766496
[TBL] [
